Navigation Links
North Shore-LIJ Cancer Institute doctors' editorial published
Date:3/19/2014

LAKE SUCCESS, NY Two North Shore-LIJ Cancer Institute doctors, world-renowned for their research in chronic lymphocytic leukemia (CLL), weigh in on a German study of a new drug therapy for CLL in the March 20 edition of the New England Journal of Medicine, the North Shore-LIJ Health System announced today.

CLL is one of the most common forms of blood cancers, usually affecting those later in life. In an editorial written by Kanti Rai, MD, chief of CLL Research and Treatment Program for the health system, and Jacqueline Barrientos, MD, a research hematologist on staff at the CLL Program, they point out that an important factor in the study is that most of the nearly 800 subjects are elderly with coexisting other health issues.

Until now, researchers have skipped this population in favor of younger and healthier subjects, say the doctors, who also have academic appointments at Hofstra North Shore-LIJ School of Medicine. However, the average age of CLL patients at diagnosis is 72, and most usually have other health problems.

The study focused on the use of obinutuzumab, an antibody that binds to the protein CD20, in subjects with previously untreated CLL and coexisting conditions. Most cases of CLL start in white blood cells that have CD20 on their surface.

Researchers compared the benefits of obinutuzumab with that of another antibody rituximab, which also attacks CD20. Both drugs were combined with the chemotherapy drug chlorambucil. They found that subjects receiving obinutuzumab-chlorambucil had an average of 26.7 months progression-free of the disorder compared to 16.3 for those given rituximab-chlorambucil. To read more about the study, visit the New England Journal of Medicine online.

Findings of the study will have an important impact on future CLL research, explained Dr. Rai, who is also an investigator at North Shore-LIJ's Feinstein Institute for Medical Research. "The researchers' work will encourage future use of obinutuzumab in combination with other drugs and help shape the clinical landscape of CLL in the next decade."


'/>"/>

Contact: Diane O'Donnell
dodonnell2@nshs.edu
516-465-2615
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. New online portal, app provide information on tsunami zones in the Northwest
2. A North American first at the Montreal Heart Institute
3. Symtrex Inc. Signs Up with ImmuneSecurity to Launch LogInspect to the North American Market
4. Northwestern launches comprehensive program for patients with bicuspid aortic valve disease
5. Northwestern Medicine hosts the National Marfan Foundations Annual Conference
6. Northwestern researchers investigate treatment for tumor cells in spinal fluid
7. North Texas Cities to Start West Nile Spraying Thursday
8. Northeasterns Barnett Institute announces formation of leading analytics company, BioAnalytix, LLC
9. Power Slowly Returns to Much of Northeast After Sandy
10. Kessler awarded $2 million federal grant for Northern NJ Traumatic Brain Injury System
11. Heart Health Worst in the South, Best in Northeast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: